Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion

Jin-jiang YANG; Liu-jiang LI; Shi-jun SHEN; Zhao-xiang LI; Yong YANG; Guo-jian LI

doi:10.12259/j.issn.2095-610X.S20201122

Volume 41 Issue 11

Dec. 2020

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2020 > 41(11): 83-87

Jin-jiang YANG, Liu-jiang LI, Shi-jun SHEN, Zhao-xiang LI, Yong YANG, Guo-jian LI. Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion[J]. Journal of Kunming Medical University, 2020, 41(11): 83-87. doi: 10.12259/j.issn.2095-610X.S20201122

Citation:

Jin-jiang YANG, Liu-jiang LI, Shi-jun SHEN, Zhao-xiang LI, Yong YANG, Guo-jian LI. Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion[J]. Journal of Kunming Medical University, 2020, 41(11): 83-87. doi: 10.12259/j.issn.2095-610X.S20201122

Citation:

Jin-jiang YANG, Liu-jiang LI, Shi-jun SHEN, Zhao-xiang LI, Yong YANG, Guo-jian LI. Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion[J]. Journal of Kunming Medical University, 2020, 41(11): 83-87. doi: 10.12259/j.issn.2095-610X.S20201122

PDF( 638 KB)

Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion

doi: 10.12259/j.issn.2095-610X.S20201122

Jin-jiang YANG^{1, 2},
Liu-jiang LI^{1, 2},
Shi-jun SHEN³,
Zhao-xiang LI^{1, 2},
Yong YANG^{1, 2
,
,},
Guo-jian LI^{1, 2
,
,}

1.
Dept. of Vascular Surgery，The Fourth Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650021
2.
Vascular Surgery Center of Yunnan Province，Kunming Yunnan 650021
3.
Dept. of Stomach and Small Intestine Surgery，The Third Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650118，China

Received Date: 2020-08-23
Available Online: 2020-12-03
Publish Date: 2020-11-25

Abstract

Abstract

Objective To study the efficacy and safety of rivaroxaban after stent implantation of the femoral popliteal atherosclerosis occlusion stent. Methods Eighty-seven patients who met the criteria were randomly divided into 45 cases in the treatment group and 42 cases in the control group. There was no statistically significant difference in the general information between the two groups. The treatment group was given rivaroxaban tablets 10 mg each time, po, qd and aspirin enteric-coated tablets 100 mg each time, po, qd; the control group was given aspirin enteric-coated tablets 100 mg, po, qd each time, both groups were given Atorvastatin 10 mg, po, qd and Beraprost sodium tablets 40 μg, po, tid, all patients were urged to quit smoking. Observe the relevant efficacy indicators such as ABI, claudication distance, stent restenosis, stent mural thrombosis, and secondary intervention rate of the two groups of patients on the day of postoperative day, 3 months and 6 months after treatment, and the safety indicators such as adverse drug reactions, major adverse cardiacand cerebrovascular events, minor and major bleeding, the results were analyzed statistically. Results At 6 months, there were differences in the stent mural thrombosis, ankle brachial index and claudication distance between the two groups（P < 0.05）, no significant difference in in-stent restenosis（P > 0.05）, There was no statistically significant difference in the log-rank test of the second intervention rate between the two groups（P > 0.05）, and there was no statistical difference in safety comparison between the two groups（P > 0.05）. Conclusion Rivaroxaban combined with aspirin can significantly reduce stent mural thrombosis and delay the decline in postoperative ABI and claudication distance, which may benefit the long-term prognosis of patients.
- Rivaroxaban,
- Femoral popliteal atherosclerosis occlusion,
- In-stent restenosis,
- Mural thrombosis in the stent,
- Safety,
- Efficacy

FullText(HTML)

References(11)

References

[1]	中华医学会外科学分会血管外科学组. 下肢动脉硬化闭塞症诊治指南[J].中华普通外科学文献(电子版),2006,10(01):1-18.
[2]	袁丁,赵纪春,王铁皓,等. 下肢动脉硬化闭塞症最新指南解读及意义[J].中国普外基础与临床杂志,2018,25(01):25-31.
[3]	苏少飞,李全成,陈林宝,等. 抗凝联合抗血小板预防糖尿病下肢动脉硬化闭塞症支架植入后再狭窄的效果观察[J].中国糖尿病杂志,2017,25(03):218-221. doi: 10.3969/j.issn.1006-6187.2017.03.006
[4]	Suzuki K,Iida O,Soga Y,et al. Long-term results of the S.M.A.R.T. Control(TM)stent for superficial femoral artery lesions,J-SMART registry[J]. Circ J:Official Journal of the Japanese Circulation Society,2011,75(4):939-944. doi: 10.1253/circj.CJ-10-1029
[5]	毛由军,李晓强. 下肢动脉支架内再狭窄的诊断和治疗[J].中华普通外科学文献(电子版),2020,1(14):76-80.
[6]	Dagher N N,Modrall J G. Pharmacotherapy before and after revascularization:anticoagulation,antiplatelet agents,and statins[J]. Semin Vasc Surg,2007,20(1):10-14. doi: 10.1053/j.semvascsurg.2007.02.006
[7]	Anand S S,Bosch J,Eikelboom J W,et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease:an international,randomised,double-blind,placebo-controlled trial[J]. Lancet,2018,391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1
[8]	Zafar M U,Vorchheimer D A,Gaztanaga J,et al. Antithrombotic effects of factor Xa inhibition with DU-176b:Phase-I study of an oral,direct factor Xa inhibitor using an ex-vivo flow chamber[J]. Thromb Haemost,2007,98(4):883-888.
[9]	Sanmartín M,Bellmunt S,Cosín-Sales J,et al. Role of rivaroxaban in the prevention of atherosclerotic events[J]. Expert Rev Clin Pharmacol,2019,12(8):771-780. doi: 10.1080/17512433.2019.1637732
[10]	Akkaya G,Bilen Ç,Gençpınar T,et al. Effects of rivaroxaban on intimal hyperplasia and smooth muscle cell proliferation at the carotid artery anastomosis site in rabbits[J]. Anatol J Cardiol,2017,18(4):261-265.
[11]	Woźniak E,Broncel M,Bukowska B,et al. The Protective effect of dabigatran and rivaroxaban on DNA oxidative changes in a model of vascular endothelial damage with oxidized cholesterol[J]. Int J Mol Sci,2020,21(6):1953. doi: 10.3390/ijms21061953

Relative Articles(20)

Relative Articles

[1]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[2]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[3]	Jianmei LI, Yanling JIN. Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma. Journal of Kunming Medical University, 2023, 44(6): 120-125. doi: 10.12259/j.issn.2095-610X.S20230610
[4]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[5]	Xing LIU, Chunhong YU, Weixian LI, Bing OUYANG, Lingjun SHEN. A Randomized Controlled Study on the Treatment of Multidrugresistant Tuberculosis with a Regimen Containing Bedaquiline Fumarate Tablets. Journal of Kunming Medical University, 2023, 44(12): 150-158. doi: 10.12259/j.issn.2095-610X.S20231224
[6]	Rui CUN, Meiling CHEN. Efficacy and Clinical Application of Flunarizine Combined with Ginkgo damo in Treatment of Senile Vertigo. Journal of Kunming Medical University, 2022, 43(7): 116-120. doi: 10.12259/j.issn.2095-610X.S20220703
[7]	Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325
[8]	Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141
[9]	Luo Wei , Wang Shun Jun , Fang Ke Wei , Chen Tao , Chen Rong Qiong , Wang Hui Tao , Yang Bo Wei , Guo Hai Xiang , Zhang Hai Yan , Li Pei , Ke Chang Xing , Liu Jian He . . Journal of Kunming Medical University, 2019, 40(12): 124-129.
[10]	Jin Ying . The Short-term and Long-term Clinical Effect of Leep Knife Treatment of Chronic Cervicitis. Journal of Kunming Medical University,
[11]	Chang Song Jie . The Clinical Efficacy and Safety of Decreasing Blood Uric Acid by Benzene Bromine Malone in Treatment of Hyperuricemia with Elderly Hypertension and Diabetes Mellitus. Journal of Kunming Medical University,
[12]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[13]	Ke Zi Li . . Journal of Kunming Medical University,
[14]	Zeng Hai Ping . . Journal of Kunming Medical University,
[15]	Wang Ji Cai . . Journal of Kunming Medical University,
[16]	Yang Yong Rui . . Journal of Kunming Medical University,
[17]	Hu Hai Yan . . Journal of Kunming Medical University,
[18]	Liu Yue Bo . . Journal of Kunming Medical University,
[19]	Yang Xi Yun . . Journal of Kunming Medical University,
[20]	Wang Ji Cai . . Journal of Kunming Medical University,